VIR Vir Biotechnology Inc

Price (delayed)

$29.47

Market cap

$3.9B

P/E Ratio

3.17

Dividend/share

N/A

EPS

$9.3

Enterprise value

$3.21B

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are ...

Highlights
The net income has surged by 130% since the previous quarter
The EPS has surged by 129% since the previous quarter
VIR's quick ratio has surged by 50% year-on-year but it is down by 19% since the previous quarter
The debt has soared by 99% YoY
VIR's gross margin is down by 7% year-on-year

Key stats

What are the main financial stats of VIR
Market
Shares outstanding
132.38M
Market cap
$3.9B
Enterprise value
$3.21B
Valuations
Price to earnings (P/E)
3.17
Price to book (P/B)
1.95
Price to sales (P/S)
1.67
EV/EBIT
1.96
EV/EBITDA
1.94
EV/Sales
1.38
Earnings
Revenue
$2.33B
EBIT
$1.64B
EBITDA
$1.65B
Free cash flow
$555.05M
Per share
EPS
$9.3
Free cash flow per share
$4.2
Book value per share
$15.12
Revenue per share
$17.61
TBVPS
$21.48
Balance sheet
Total assets
$2.89B
Total liabilities
$886.12M
Debt
$132.81M
Equity
$2B
Working capital
$1.87B
Liquidity
Debt to equity
0.07
Current ratio
3.66
Quick ratio
3.56
Net debt/EBITDA
-0.42
Margins
EBITDA margin
71.1%
Gross margin
93.3%
Net margin
52.3%
Operating margin
68.5%
Efficiency
Return on assets
68.4%
Return on equity
96.4%
Return on invested capital
202.8%
Return on capital employed
75.1%
Return on sales
70.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VIR stock price

How has the Vir Biotechnology stock price performed over time
Intraday
7.95%
1 week
15.7%
1 month
11.21%
1 year
-23.05%
YTD
-29.62%
QTD
15.7%

Financial performance

How have Vir Biotechnology's revenue and profit performed over time
Revenue
$2.33B
Gross profit
$2.17B
Operating income
$1.59B
Net income
$1.22B
Gross margin
93.3%
Net margin
52.3%
The net income has surged by 130% since the previous quarter
The company's operating margin has surged by 113% YoY and by 78% QoQ
VIR's revenue has soared by 112% from the previous quarter
The company's gross profit has surged by 111% QoQ

Growth

What is Vir Biotechnology's growth rate over time

Valuation

What is Vir Biotechnology stock price valuation
P/E
3.17
P/B
1.95
P/S
1.67
EV/EBIT
1.96
EV/EBITDA
1.94
EV/Sales
1.38
The EPS has surged by 129% since the previous quarter
VIR's price to book (P/B) is 65% lower than its last 4 quarters average of 5.1
Vir Biotechnology's equity has increased by 40% from the previous quarter
VIR's revenue has soared by 112% from the previous quarter
The price to sales (P/S) is 90% lower than the last 4 quarters average of 15.0

Efficiency

How efficient is Vir Biotechnology business performance
The return on sales has surged by 113% year-on-year and by 40% since the previous quarter
The return on invested capital has surged by 90% since the previous quarter
Vir Biotechnology's return on assets has surged by 73% QoQ
Vir Biotechnology's return on equity has surged by 69% QoQ

Dividends

What is VIR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VIR.

Financial health

How did Vir Biotechnology financials performed over time
Vir Biotechnology's total assets has surged by 154% YoY and by 48% QoQ
The company's total liabilities has surged by 83% YoY and by 70% QoQ
The debt is 93% less than the equity
The debt has soared by 99% YoY
Vir Biotechnology's equity has increased by 40% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.